| 产品描述: | Upidosin (Rec 15/2739) 是 α-1 肾上腺素受体 (α-1 AR) 拮抗剂。Upidosin 具有对 α-1A AR 亚型的中等选择性。Upidosin 具有尿选择性,在尿道和前列腺有更高的亲和力,Kb 值为 2-3 nM,在耳动脉和主动脉的 Kb 值为 20-100 nM。Upidosin 抑制 [3H]prazosin 与人 α-1A 肾上腺素受体结合。Upidosin 可用于尿道梗阻的研究。 |
| 体外研究: |
Upidosin is one of the most potent compounds action on the prostate with comparing the apparent pKB values, but its potency is slightly lower than that of tamsulosin and is higher than the potencies of prazosin, terazosin and 5-methylurapidil. Upidosin shows binding affinities to cloned humanα1A, humanα1B, humanα1D adrenoceptors with pKi value of 9.0, 7.5 and 8.6, respectively. |
| 体内研究: |
Upidosin shows greater selectivity than any other α-1 AR antagonist terazosin and tamsulosin in the anesthetized dog. Upidosin (1-300 μg/kg; i.v.) is a more potent antagonist of phenylephrine mediated increases in prostatic pressure with a pA2 value of 8.74 compared to blood pressure with a pA2 value of 7.51. |
| 参考文献: |
1. Leonardi A, et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther. 1997 Jun;281(3):1272-83.
2. Testa R, et al. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46.
3. Kenny BA, et al. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.955 ml |
9.773 ml |
19.546 ml |
| 5 mM |
0.391 ml |
1.955 ml |
3.909 ml |
| 10 mM |
0.195 ml |
0.977 ml |
1.955 ml |
| 50 mM |
0.039 ml |
0.195 ml |
0.391 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |